Exavir Therapeutics develops ultra-long-acting prodrugs for antiviral therapies, focusing on extending dosing intervals for HIV treatment and prevention. The pipeline includes candidates based on cabotegravir, dolutegravir, and tenofovir designed for infrequent administration. This approach aims to improve adherence and convenience for patients living with or at risk of HIV and HBV co-infection.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patient adherence to daily oral therapies for chronic viral infections like HIV is low, leading to suboptimal treatment outcomes and continued disease transmission. Existing treatments often require frequent dosing, which can be burdensome for patients and contribute to non-compliance.
Solution
Exavir Therapeutics is developing ultra-long-acting injectable therapies using a prodrug nanomedicine technology that extends the half-life of small molecule drugs by over 100 times. This approach aims to improve patient adherence by significantly reducing the frequency of dosing required for effective treatment of chronic viral infections and CNS disorders. By enabling less frequent injections, Exavir's technology offers convenience, safety, and efficacy advantages compared to existing daily oral therapies, potentially leading to better patient outcomes and reduced disease transmission. The company's initial focus is on developing a long-acting injectable for HIV.
Target Audience
The primary target audience includes individuals with chronic viral infections such as HIV, as well as healthcare providers seeking to improve patient adherence and treatment outcomes.
Features
- Prodrug nano-formulation technology that prolongs the apparent half-life of small molecule drugs by >100X.
- Ultra-long-acting dosing regimens for improved patient convenience and adherence.
- Novel composition of matter enabling extended release profiles.
- Potential applications across HIV, opioid use disorder, and schizophrenia.